All Stories

  1. Long-Term Outcomes Following Suppressive Antibiotic Therapy: A 10-Year Cohort Study
  2. Varicella zoster virus reactivation episodes and vaccination uptake in Spleen Australia registrants
  3. A nationwide Australian cross-sectional study assessing current management and infection prevention practices after Splenic Artery Embolisation (SAE) following trauma
  4. Pyogenic ventriculitis in meningococcal meningitis: A case report
  5. Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE study
  6. HIV treatment outcomes after 10 years on ART in the TREAT Asia Observational Database (TAHOD) and Australian HIV Observational Database (AHOD)
  7. The use of long-term antibiotics for suppression of bacterial infections
  8. The burden of skin and soft tissue, bone and joint infections in an Australian cohort of people who inject drugs
  9. Changes in atherosclerotic cardiovascular disease risk over time among people living with HIV
  10. Impact of COVID-19 on people with non-functioning spleens in Australia
  11. Addressing atherosclerotic cardiovascular disease risk in persons with HIV
  12. More evidence for inequitable COVID-19 outcomes in people with HIV
  13. Primary cardiovascular prevention in people with HIV: what's the score?
  14. Successful expanded clinic network collaboration and patient tracing for retention in HIV care
  15. Human herpes virus 8-related illness: still with us
  16. Long term antibiotic prescribing in the community: 6 years of Australian national data
  17. New diagnosis of HIV with Cryptococcus neoformans infection presenting as a pleural syndrome
  18. The impact of the COVID-19 pandemic on people with HIV in Victoria, Australia: 1 year later
  19. Successful Expanded Clinic Network Collaboration and Patient Tracing for Retention in HIV Care
  20. Integrating Hepatitis C Virus Treatment Programs Within Community Mental Health
  21. Outcomes in Medicare‐ineligible people living with human immunodeficiency virus in a large healthcare network in Melbourne 2004–2019
  22. Congenital asplenia study: clinical and laboratory characterisation of adults with congenital asplenia
  23. Reductions in Antibiotic Prescribing in Australia During the SARS-CoV-2 Pandemic: National Prescribing Data
  24. When pandemics collide: measuring the impact of coronavirus disease 2019 on people with HIV
  25. Long-Term Outcomes in Patients on Life-Long Antibiotics: A Five-Year Cohort Study
  26. Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV
  27. Physical function limitation among gay and bisexual men aged ≥55years with and without HIV: findings from the Australian Positive and Peers Longevity Evaluation Study (APPLES)
  28. Hepatitis C virus in people with serious mental illness: An analysis of the care cascade at a tertiary health service with a pilot ‘identify and treat’ strategy
  29. SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study
  30. COVID ‐19: looking backward
  31. HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
  32. Underutilised human immunodeficiency virus testing in the setting of invasive pneumococcal disease
  33. The Clinical and Financial Burden of Spinal Infections in People who Inject Drugs
  34. IgG4-related disease masquerading as a fungating groin lesion in a patient with HIV and incomplete immune reconstitution
  35. The impact of the COVID-19 pandemic on people living with HIV in Victoria, Australia
  36. A novel case of bilateral tubo-ovarian abscesses attributed to Ruminococcus gnavus without gastrointestinal involvement
  37. Routine testing for hyposplenism in a lupus clinic diagnoses; new cases and opportunities for intervention
  38. Breaking the fourth wall: Integrating quality into HIV care
  39. Trends in practice: attitudes and challenges in the diagnosis, treatment and management of HIV infection in Australia
  40. Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study
  41. Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study
  42. Case Report: Japanese Encephalitis Associated with Chorioretinitis after Short-Term Travel to Bali, Indonesia
  43. Acceptability of injectable anti-retroviral therapy in Australian travellers with HIV
  44. Coronavirus disease 2019 (COVID‐19): not one epidemic but four
  45. Platelet phenotype and function in the absence of splenic sequestration (Review)
  46. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV
  47. The burden of infective endocarditis in an Australian cohort of people who inject drugs
  48. Intermittent negative blood cultures in Staphylococcus aureus bacteremia; A retrospective study of 1071 episodes
  49. Surveillance of life-long antibiotics—A cross-sectional cohort study assessing patient attitudes and understanding of long-term antibiotic consumption
  50. HIV presenting as AIDS in previously undiagnosed tourists in a low-prevalence setting
  51. Review of HIV testing recommendations in Australian specialty guidelines for HIV indicator conditions: a missed opportunity for recommending testing?
  52. Post-splenectomy sepsis: preventative strategies, challenges, and solutions
  53. Prevalence and distribution of functional splenic tissue after splenectomy
  54. Implementation of “Treat‐all” at adult HIV care and treatment sites in the Global Ie DEA Consortium: results from the Site Assessment Survey
  55. Healthy, safe and effective international medical student electives: a systematic review and recommendations for program coordinators
  56. Infectious diseases physician attitudes to long-term antibiotic use
  57. Response to letter to editor regarding Lin et al ‘Prevalence of HIV indicator conditions in late presenting patients with HIV: a missed opportunity for diagnosis?’
  58. Management of gonorrhoea in a hospital network: are we following best practice?
  59. Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific
  60. Human immunodeficiency virus-infected young people in Australia: data from the Australian HIV Observational Database
  61. Cardiovascular disease and diabetes in HIV-positive and HIV-negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study
  62. Prevalence of HIV indicator conditions in late presenting patients with HIV: a missed opportunity for diagnosis?
  63. Initial modelling and updates on cost effectiveness from the first 10 years of a spleen registry
  64. Are Bone Disease and Cardiovascular Disease Risk Correlated in an HIV Cohort?
  65. Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals
  66. Chronic kidney disease in Australian Human Immunodeficiency Virus-infected patients: Analysis of the Australian HIV Observational Database
  67. Impact of a spleen registry on optimal post-splenectomy vaccination and care
  68. HIV in practice: current approaches and challenges in the diagnosis, treatment and management of HIV infection in Australia
  69. Life-long antimicrobial therapy: where is the evidence?
  70. Selected state of the art research in internal medicine, 2017
  71. Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine
  72. Physician testing for HIV in patients treated with tenofovir disoproxil fumarate and lamivudine monotherapy for hepatitis B virus
  73. Increasing Prevalence and Risk of Chronic Kidney Disease in Human Immunodeficiency Virus–Infected Individuals: Changing Demographics Over a 6-Year Period
  74. Understanding of the significance and health implications of asplenia in a cohort of patients with haemaglobinopathy: possible benefits of a spleen registry
  75. Cryptococcal/CSF ventricular levels on MRI brain in a man with AIDS
  76. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
  77. High rates of potentially infectious exposures between immunocompromised patients and their companion animals: an unmet need for education
  78. The impact of changes in HIV management guidelines on time to treatment initiation in Australia
  79. Integrase-resistant HIV in an antiretroviral-naive patient in Australia
  80. Surveillance of life-long antibiotics: a review of antibiotic prescribing practices in an Australian Healthcare Network
  81. Cryptococcemia in primary HIV infection
  82. Isn't it time to talk about antiretroviral stewardship?
  83. Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 4...
  84. Tenofovir Therapy for Hepatitis B May Be Commonly Prescribed Without HIV Testing
  85. Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study
  86. Treatment and disease outcomes of migrants from low- and middle-income countries in the Australian HIV Observational Database cohort
  87. Low rates of endocarditis in healthcare-associated Staphylococcus aureus bacteremia suggest that echocardiography might not always be required
  88. A history of infection with varicella is strongly predictive of the presence of varicella-zoster virus antibodies in a heterogenous Australian HIV cohort
  89. Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)
  90. Acute HIV infection presenting as erythema multiforme in a 45-year-old heterosexual man
  91. Caught in the act… a case of fulminant amoebic colitis
  92. International travel in the immunocompromised patient: a cross-sectional survey of travel advice in 254 consecutive patients
  93. Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care
  94. Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia
  95. Latent infection in HIV-positive refugees and other immigrants in Australia
  96. An analysis of the thromboembolic outcomes of 2472 splenectomized individuals
  97. Mycobacterium haemophilumbone and joint infection in HIV/AIDS: case report and literature review
  98. Correction: Recent trends in early stage response to combination antiretroviral therapy in Australia
  99. Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men
  100. Acanthamoeba Encephalitis: Isolation of Genotype T1 in Mycobacterial Liquid Culture Medium
  101. HIV and aging: insights from the Asia Pacific HIV Observational Database (APHOD)
  102. What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore
  103. Macrophage migration inhibitory factor
  104. Determinants of Viremia Copy-Years in People With HIV/AIDS After Initiation of Antiretroviral Therapy
  105. The Significance of HIV ‘Blips’ in Resource-Limited Settings: Is It the Same? Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD)
  106. The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD)
  107. Recent trends in early stage response to combination antiretroviral therapy in Australia
  108. C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals
  109. Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for ‘Test and Treat’ Prevention Strategy
  110. The inside story. Physicians’ views on digital ano-rectal examination for anal cancer screening of HIV positive men who have sex with men
  111. HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation
  112. The two-edged sword: vasculitis associated with HIV and hepatitis C coinfection
  113. Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia
  114. Low Risk of Japanese Encephalitis in Short‐Term Australian Travelers to Asia
  115. Determining research priorities for clinician-initiated trials in infectious diseases
  116. Vitamin d deficiency impacts on expression of toll-like receptor-2 and cytokine profile: a pilot study
  117. Shooting At the DARC: Potential Issues with Species-Specific Antimalarials
  118. Visiting friends and relatives may be a risk for non-adherence for HIV-positive travellers
  119. Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia
  120. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD)
  121. Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
  122. Acute Mediastinal Melioidosis: Diagnosis By Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
  123. Splenectomy sequelae: an analysis of infectious outcomes among adults in Victoria
  124. New HIV diagnosis after occupational exposure screening: the importance of reporting needlestick injuries
  125. Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia
  126. CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts
  127. Rat bite fever as a presenting illness in a patient with AIDS
  128. Splenectomy Associated Changes in IgM Memory B Cells in an Adult Spleen Registry Cohort
  129. Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected Patients
  130. Comment on: The DART Trial: 'The Doctor's Dilemma' revisited
  131. The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD
  132. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients
  133. Trends in detectable viral load by calendar year in the Australian HIV observational database
  134. Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections
  135. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
  136. The Influence of Splenectomy on the Infectious Complications and Outcomes of people With HIV: Marked, Sustained Elevation in Risk of Severe Infection With Bacteria Including Streptococcus pneumoniae
  137. Cardiac computed tomography in endocarditis
  138. Autoimmune haemolytic anaemia: an unusual presentation of HIV seroconversion disease
  139. CORRIGENDUM
  140. Re: Published article - patient knowledge of the risks of post-splenectomy sepsisANZ J. Surg.2008; 78: 867-70
  141. Duffy antigen expression on reticulocytes does not alter following blood loss in an autologous donation model
  142. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management
  143. Duffy Antigen Polymorphisms Do Not Alter Progression of HIV in African Americans in the MACS Cohort
  144. Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy
  145. HIV infection and high density lipoprotein metabolism
  146. Guidelines for the prevention of sepsis in asplenic and hyposplenic patients
  147. Unrecognised vitamin D deficiency: low concentrations in African migrants with HIV in Australia
  148. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993?2006
  149. Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART
  150. Acute pancreatitis caused by tipranavir/ritonavir-induced hypertriglyceridaemia
  151. Macrolide use and the risk of vascular disease in HIV-infected men in the Multicenter AIDS Cohort Study
  152. Cambodian-born individuals diagnosed with HIV in Victoria: epidemiological findings and health service implications
  153. Cost-effectiveness of a post-splenectomy registry for prevention of sepsis in the asplenic
  154. Occupational exposures experienced by medical students during overseas electives
  155. Rat-bite fever septic arthritis: illustrative case and literature review
  156. ADHERENCE TO GUIDELINES FOR PREVENTION OF POSTSPLENECTOMY SEPSIS. AGE AND SEX ARE RISK FACTORS: A FIVE-YEAR RETROSPECTIVE REVIEW
  157. A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy
  158. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment
  159. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database
  160. Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction
  161. Eosinophilic folliculitis
  162. The Use of Antibiotics as Secondary Prevention for Cardiac Events
  163. Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient
  164. Chlamydia pneumoniae in HIV-infected patients and controls assessed by a novel whole blood interferon-γ assay, serology and PCR
  165. Clostridium septicum Bacteremia Without Gas Gangrene as a Late Consequence of a Contaminated Wound
  166. Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management
  167. Disseminated Mycobacterium avium-intracellulare Complex (MAC) Infection in the Era of Effective Antiretroviral Therapy
  168. Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis
  169. Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virus–Infected Patients
  170. Changing Spectrum of Mortality Due to Human Immunodeficiency Virus: Analysis of 260 Deaths during 1995-1999
  171. Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of theP. vivaxligand required for blood-stage infection
  172. Letter to the Editor
  173. Differential expression of the Duffy antigen receptor for chemokines according to RBC age and FY genotype
  174. Emergence of FY*A null in a Plasmodium vivax -endemic region of Papua New Guinea
  175. Human Immunodeficiency Virus 1 Protease Inhibitors in Clinical Practice
  176. GBV-C/HGV infection in HIV-infected patients
  177. Hepatitis G Virus RNA Is Common in AIDS Patients' Plasma but Is Not Associated With Abnormal Liver Function Tests or Other Clinical Syndromes
  178. Transmissible spongiform encephalopathy and new variantCreutzfeldt-Jakob disease
  179. Piroplasmosis
  180. Postpartum Epidural Abscess Due to Group BStreptococcus
  181. Diffuse alveolar damage following a single administration of a cyclophosphamide containing chemotherapy regimen
  182. CD4 lymphocyte counts in HIV/AIDS patients with intercurrent illness